Publisher
Springer Berlin Heidelberg
Reference102 articles.
1. Assikis VJ,NevenP,JordanVC,VergoteI(1996)A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur J Cancer 32:1464–1476
2. Baer PG, Willson TM, Morris DC(1994)Lack of effect on bone of 28-days treatment of OVX and intact rats with a pure anti-estrogen (ICI 164384). Calcified Tissue Int 54:338 (Abstract)
3. Black LJ, Good RL(1980)Uterine bioassay of tamoxifen, trioxifene and a new estrogen antagonist (LY117018) in rats and mice. Life Sci. 26:1453–1458
4. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Bensch WR, Frolik CA, Termine JD, Bryant HU(1994) Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 93:63–69
5. Bowler J,Lilley TJ,Pittam JD,WakelingAE(1989)Novel steroidal pure antiestrogens. Steroids 54:71–99